P2, N=15, Active, not recruiting, St Vincent's Hospital Sydney | Recruiting --> Active, not recruiting

While both TCT and QCT have infection, the QCT group may be at a higher risk, hence highlighting the need for vigilance and adequate prophylaxis.

Silencing p53 with siRNA abolished all synergistic effects in A2780 cells. Niraparib and trabectedin combination therapy impairs DNA repair in BRCA-proficient ovarian cancer, leading to synthetic lethality through p53-dependent apoptosis.

Pretreatment with M. oleifera successfully mitigated CP-induced oxidative and inflammatory changes, as well as ovarian tissue damage, but failed to reverse serum hormonal imbalances. These findings demonstrate the protective potential of M. oleifera leaf extract against CP-induced ovarian toxicity, likely mediated by the synergistic antioxidant, anti-inflammatory, and organ-protective properties of its bioactive components.

P1, N=36, Not yet recruiting, Jieyang People's Hospital

P2, N=41, Not yet recruiting, Milton S. Hershey Medical Center

LEV (0.05 and 0.1 mg/kg, i.p.) and fenofibrate (FF) (80 mg/kg, p.o.) were given daily for 14 days. LEV 0.1 and FF 80 significantly reversed these changes toward normal and showed nephroprotective potential. Thus, seeing the protective effect of LEV on CP-intoxicated mice, we conclude that LEV may be used as an adjuvant with CP in cancer, however, it needs more studies with the direct cancer model to confirm the claim.

P=N/A, N=26, Completed, Englewood Hospital and Medical Center | Recruiting --> Completed | N=60 --> 26 | Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2022 --> Oct 2024

P1, N=50, Recruiting, University of Alabama at Birmingham | Not yet recruiting --> Recruiting

Our study demonstrates that the CD8+-T-cell-dependent anti-tumor mechanisms of CTX critically involve the cGAS-STING-IFN-I axis, IFN-I response, and STING-independent cGAS function in host myeloid cells. These findings suggest the deployment of CTX in treating advanced solid tumor to bypass the often-failed IFN-I production by tumor cells due to the chronic activation of intrinsic cGAS-STING caused by chromosomal instability.

Additionally, immunohistochemical analysis demonstrated that CP markedly upregulated iNOS expression in cardiac tissue, whereas chrysin dose-dependently downregulated iNOS, achieving complete normalization at the highest dose. Collectively, these findings suggest that chrysin exerts significant cardioprotective effects against CP-induced cardiotoxicity, likely through the modulation of Treg expression, attenuation of apoptosis, and suppression of iNOS-mediated inflammatory responses, underscoring its potential as an adjunctive therapy in chemotherapy-associated cardiac complications.

One or 3 days after preconditioning, the patients underwent busulfan-based myeloablative conditioning and HLA haploidentical or matched related donor stem cell infusion. At the last follow-up, both patients were in good health and in MRD-negative complete remissions after 11 and 17 months after alloSCT, respectively. The safety and efficacy of upfront sequential alloSCT indicate the need to evaluate this approach for adverse risk of AML in clinical trials.

REV-ERBα agonists can significantly attenuate the hepatotoxicity of CPA by regulating CYP2B10. The discovery of REV-ERBα as novel regulator for CYP2B10 will help to establish new targets to improve drug efficacy or reduce toxicity.

P1, N=1, Active, not recruiting, University of Calgary | Not yet recruiting --> Active, not recruiting | Phase classification: PN/A --> P1

P1/2, N=118, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | Trial completion date: Feb 2035 --> Aug 2035 | Trial primary completion date: Feb 2025 --> Aug 2025

These changes were correlated with improved clinical outcomes. Our findings underscore the therapeutic potential and safety of combining rcIL-15 and metronomic cyclophosphamide for the treatment of various canine cancers.

Rates of AEs, serious AEs, and events of clinical interest were similar between acalabrutinib-containing arms and consistent with the known safety profiles of acalabrutinib and obinutuzumab. Efficacy and safety of acalabrutinib-containing arms were maintained, with longer PFS in both acalabrutinib arms vs chlorambucil-obinutuzumab including in patients with high-risk features.

P2, N=118, Completed, Beth Israel Deaconess Medical Center | Trial completion date: Apr 2023 --> Apr 2025

P1, N=18, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting

P=N/A, N=10, Recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jan 2023 --> Nov 2025

The primary objective of this study is to identify and validate BRCA-associated FAMGs that can serve as prognostic indicators and provide insights into immune system function, while also offering evidence to support the development of fatty acid metabolism-related molecularly targeted therapeutics. Consequently, FAMGs and their interactions with the immune system, as well as their role in BRCA, may emerge as promising therapeutic targets.

PA in MM patients during induction is feasible and can improve fatigue, depression, TUGT, grip strength, comorbidities and QoL. More sport intervention offers are warranted to advance exercising in MM.

P2, N=49, Recruiting, VIVUS LLC

P=N/A, N=272, Active, not recruiting, Jazz Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jun 2030 --> Jun 2025 | Trial primary completion date: Jun 2030 --> Jun 2025

P3, N=126, Recruiting, Universität Münster | Trial primary completion date: Dec 2025 --> Aug 2026

The review also discusses potential therapeutic interventions, including phytotherapeutic agents, that target NLRP3 inflammasome activation to mitigate CPM-induced organ injury. By highlighting the crucial role of NLRP3 in CPM-related toxicity, this review provides a foundation for future research aimed at developing novel therapeutic strategies to minimize adverse effects and improve patient outcomes.

Randomization 3:1:3 to LI+/-CIZ (cyclophosphamide, indomethacin, and zinc)+SOC, or SOC (standard of care) alone. No excess safety issues were reported for LI over SOC alone post-surgery. NCT01265849, EUDRA:2010-019952-35.

Patients received a fludarabine/cyclophosphamide conditioning followed by adoptive immunotherapy with IL2-activated haploidentical NK cells. In addition, all patients showed a relative decrease in alpha-fetoprotein (AFP) expression levels after one month. This study demonstrated the safety and feasibility of infusing high doses of ex vivo expanded NK cells after conditioning with transient side effects.

Arsenic trioxide (ATO), carboplatin (CP), and cyclophosphamide (CY) are used to treat various cancers. The combination of ATO, CP, and CY induces synergistic effects in promoting apoptosis and autophagy in TNBC cell lines. These findings suggest that this combination therapy could be a promising approach to enhancing treatment efficacy in aggressive breast cancers, offering new insights into potential therapeutic strategies.

TRAF7 could be used as a predictive biomarker and the potential therapeutic target among National Comprehensive Cancer Network (NCCN) treatment guidelines in the progression and recurrence of glioma. Lomustine, regulating cellular senescence and cell cycle could be the priority choice in glioma patients with high-level TRAF7 expression.

P=N/A, N=15, Completed, University of Sao Paulo General Hospital | Active, not recruiting --> Completed

P=N/A, N=31, Completed, Cedars-Sinai Medical Center | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Feb 2025 | Trial primary completion date: Jun 2025 --> Nov 2024

P4, N=52, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

P2, N=108, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025

P2, N=0, Withdrawn, Fondazione EMN Italy Onlus | N=30 --> 0 | Trial completion date: Aug 2027 --> Mar 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2027 --> Mar 2025

P1/2, N=0, Withdrawn, Vall d'Hebron Institute of Oncology | N=15 --> 0 | Not yet recruiting --> Withdrawn

Cyclophosphamide (CYP)-induced cystitis is a significant clinical challenge in cancer patients, characterized by inflammation, oxidative stress, and muscle dysfunction. LCSC demonstrated strong binding affinities and lower inhibition constants with key inflammatory and muscle protein receptors, including IL-1β, TNF-α, MLCP, and PKC, compared to Mesna. LCSC exhibited potent antioxidant, anti-inflammatory, and uroprotective effects in the CYP-induced rat model of cystitis as a potential therapeutic drug.

P2, N=198, Recruiting, UNICANCER | Not yet recruiting --> Recruiting

P1/2, N=30, Not yet recruiting, Eastern Hepatobiliary Surgery Hospital

P2, N=37, Completed, Universitätsklinikum Hamburg-Eppendorf | Active, not recruiting --> Completed

P1, N=60, Recruiting, Chongqing Precision Biotech Co., Ltd

P1/2, N=45, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Nov 2026 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Dec 2027